表紙
市場調査レポート

NASH (非アルコール性脂肪性肝炎) の世界市場動向・機会・予測 2015-2030年

Global NASH (Non-Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts 2015-2030

発行 Azoth Analytics 商品コード 346772
出版日 ページ情報 英文 112 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
NASH (非アルコール性脂肪性肝炎) の世界市場動向・機会・予測 2015-2030年 Global NASH (Non-Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts 2015-2030
出版日: 2015年12月10日 ページ情報: 英文 112 Pages
概要

過去5年間、世界のNASH (非アルコール性脂肪性肝炎) 市場は、若年層における肥満人口の増加に伴い、拡大してきました。現在のところ、FDAの承認を受けたNASHの治療薬はなく、その市場は巨大かつ未開の状態です。

当レポートでは、世界におけるNASH (非アルコール性脂肪性肝炎) 市場について調査分析し、市場規模・シェア・予測、セグメント別の分析、国内/外国企業の市場参入戦略、政策・規制環境、市場動向の変化と新しい機会、および競合情勢・戦略的提言などについてまとめています。

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 世界のNASH (非アルコール性脂肪性肝炎) 市場:分析

  • 世界のNASH市場概要
  • 世界のNASH市場:治療法別
  • 世界のNASHオフラベル治療薬市場:金額ベース
  • 世界のNASHオフラベル治療薬市場シェア:地域別
  • 世界のGFT505市場:規模・成長率
  • 世界のAramchol (アラムコール) 市場:規模・成長率
  • 世界のGR-MD-02市場:規模・成長率
  • 世界の2GR-MD-02市場:規模・成長率

第4章 国の分析

  • 米国のNASH市場概要
    • 米国のNAFLD (非アルコール性脂肪性肝疾患) 人口
    • 米国のNASH人口
    • 米国のNASH有病率
    • 米国のNASH診断事例数
    • 米国のNASH治療率

第5章 米国のNASH市場:治療法別

  • 米国のNASHオフラベル治療薬市場:金額ベース
  • 米国のNASH専用治療薬市場:金額ベース
  • 米国のAramchol (アラムコール) 市場:規模・成長率
  • 米国のGFT505市場:金額ベース

第6章 地域分析

  • 欧州のNASH市場概要
  • 欧州のNASH市場:治療法別
  • 欧州のAramchol (アラムコール) 市場:規模・成長率
  • 欧州のNASH GFT505市場:金額ベース

第7章 国の概要

  • 日本のNASH市場概要

第8章 NASH治療薬の臨床パイプライン分析

  • Aramchol (Galmed)
    • 化学構造
    • 臨床スケジュール
  • GFT505 (Genfit)
  • Obeticholic acid または OCA (Intercept)
  • Cenicriviroc または CVC (Tobira Therapeutics)

第9章 市場ダイナミクス

  • 促進因子
  • 課題
  • 市場動向・発展

第10章 競合情勢

  • 企業プロファイル
    • Galmed Pharmaceuticals
    • Genfit
    • Galectin Therapeutics
    • Gilead Sciences

図表リスト

目次

Executive Summary

Progressive numbers of Liver disorders along with rise in obesity will fuel the demand for NASH Drugs

The Global NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population. NASH (non-alcoholic steatohepatitis) is a large, un-tapped market with no FDA approved therapeutics. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyper Lipidemics are some of the off-label products currently used by NASH patients. Moreover, increase in number of patients suffering from fat in liver disorder is further anticipated to boost the Global NASH market in the coming years.

According to Azoth Analytics research report, “Global NASH (Non -Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) - (By Region, By Drugs - Off Label & Special Treatment, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market)”, global non-alcoholic steatohepatitis drug specific market is estimated to start growing by 2020 at a CAGR of 25.56% during 2020-2030, due to the projected product launches in 2020. Surge in cycles of clinical trials and their success rate has improved the probability of industries receiving commercial approval for NASH therapeutics by the end of 2020. Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics.

Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases. Despite of these challenges, certain key players such as Galmed Pharmaceuticals, Gilead Sciences, Novo Nordisk, Genfit, Intercept and Galectin Therapeutics are conducting extensive research on NASH therapeutics and are receiving positive results from clinical trials. But, the low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for these emerging players. The United States, which has the highest number of research initiatives concerning NASH, holds nearly half of the global market share. The chief reason behind this growth is the high prevalence of diabetes and obesity and the growing number of people suffering with these conditions. The US has the highest number cases of NASH and other non-alcoholic fatty liver diseases.

Scope of the Report

Global NASH (Non -Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) - (By Region, By Drugs - Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market) analyses the following aspects of global Alzheimer's market:

  • Global NASH Market Size, Share & Forecast
  • Segmental Analysis - By off Label , By Specific Drug and By Patient
  • Policy & Regulatory Landscape
  • Changing Market Trends & Emerging Opportunities
  • Competitive Landscape & Strategic Recommendations

Why You Should Buy This Report?

  • To gain an in-depth understanding of NASH disease and dementia market propelling globally.
  • To identify the on-going trends and anticipated growth in the next five years
  • To help industry consultants, drug and diagnostics manufacturers, vendors and dealers align their market-centric strategies
  • To obtain research based business decision and add weight to presentations and marketing material
  • To gain competitive knowledge of leading players
  • To avail limited customization in the report without any extra charges and get research data or trends added in the report as per the buyer's specific needs

Table of Contents

1. Research Methodology

2. Executive Summary

3. Global NASH Market: An Analysis

  • 3.1. Global NASH Market Overview
    • 3.1.1. Global NAFLD Population
    • 3.1.2. Global NASH Population
    • 3.1.3. Global NASH Population, By Prevalence Rate
    • 3.1.4. Global NASH Diagnosed Cases
  • 3.2. Global NASH Market by Therapeutics
  • 3.3. Global NASH Off-Label Drugs Market by Value
  • 3.4. Global NASH Off-Label Drugs Market Share by Region
  • 3.5. Global GFT505 Market: Sizing & Growth
    • 3.5.1. GFT505 Estimated Valuation
    • 3.5.2. GFT505 Market By Value
  • 3.6. Global Aramchol Market: Sizing & Growth
    • 3.6.1. Market Size: By Value
    • 3.6.2. Market Size: By Patient Volume
  • 3.7. Global GR-MD-02 Market: Sizing & Growth
    • 3.7.1. GR-MD-02 in NASH Patients
  • 3.7. 2GR-MD-02 Market By Value

4. Country Analysis

  • 4. The US Nash Market Overview
    • 4.1.1. The US NAFLD Population
    • 4.1.2. THE US NASH Population
    • 4.1.3. The US NASH Prevalence Rate
    • 4.1.4. The US NASH Diagnosed Cases
    • 4.1.5. The US NASH Treatment Rate

5. The US NASH Market by Therapeutics

  • 5.1. The US NASH Off-Label Drugs Market by Value
  • 5.2. The US NASH Specific Drugs Market by Value
  • 5.3. The US Aramchol Market: Sizing & Growth
    • 5.3.1. The US Aramchol Market: By Value
    • 5.3.2. The US Aramchol Market: By Patient Volume
    • 5.3.3. The US Aramchol Penetration Rate
    • 5.3.4. Aramchol Cost of Treatment in the US
  • 5.4. The US GFT505 Market by Value
    • 5.4.1. The US GR-MD-02 Market: Sizing & Growth
    • 5.4.2. GR-MD-02 Market By Value
    • 5.4.3. GR-MD-02 Market by Patient Volume
    • 5.4.4. GR-MD-02 Cost of Treatment in the US

6. Regional Analysis

  • 6.1. Europe NASH Market Overview
    • 6.1.1. Europe NAFLD Population
    • 6.1.2. Europe NASH Population
    • 6.1.3. Europe NASH Prevalence Rate
    • 6.1.4. Europe NASH Diagnosed Cases
    • 6.1.5. Europe NASH Treatment Rate
  • 6.2. Europe NASH Market By Therapeutics
    • 6.2.1. Europe NASH Off- Label Drugs Market By Value
    • 6.2.2. Europe NASH Off- Label Drug Market Share By Region
    • 6.2.3. Europe NASH Specific Drug Market By Value
  • 6.3. Europe Aramchol Market: Sizing & Growth
    • 6.3.1. Europe Aramchol Market By Value
    • 6.3.2. Europe Aramchol Market By Patient Volume
    • 6.3.3. Europe Aramchol Penetration Rate
    • 6.3.4. Europe Aramchol Cost of Treatment
  • 6.4. Europe NASH GFT 505 Market By Value

7. Country Overview

  • 7.1. Japan NASH Market Overview
    • 7.1.1. Japan NASH Therapeutics Market By Value.

8. Clinical Pipeline Analysis of NASH Drugs

  • 8.1. Aramchol ( Galmed)
    • 8.1.2. Chemical Structure
    • 8.1.3. Clinical Timeline
  • 8.2. GFT505 ( Genfit)
    • 8.2.1. Chemical Structure
    • 8.2.2. Clinical Timeline
  • 8.2. Obeticholic acid or OCA ( Intercept)
    • 8.2.1. Chemical Structure
    • 8.2.2. Clinical Timeline
    • 8.2.3. Mechanism of Action
  • 8.3. Cenicriviroc or CVC ( Tobira Therapeutics)
    • 8.3.1. Chemical Structure
    • 8.3.2. Route Of Administration
    • 8.3.3. Clinical Timeline
  • 8.4. Cenicriviroc or CVC ( Tobira Therapeutics)
    • 8.4.1. Chemical Structure
    • 8.4.2. Route Of Administration
    • 8.4.3. Clinical Timeline

9. Market Dynamics

  • 9.1. Drivers
  • 9.2. Challenges
  • 9.3. Market Trends & Developments

10. Competitive Landscape

  • 10.1. Company Profiling
    • 10.1.1. Galmed Pharmaceuticals
    • 10.1.2. Genfit
    • 10.1.3. Galectin Therapeutics
    • 10.1.4. Gilead Sciences

List of Figures

  • 1. Global NAFLD Population; 2015-2035E (In Million)
  • 2. Global NASH Population; 2015-2035E (In Million)
  • 3. Global Prevalence of NASH, 2014 In Percentage
  • 4. Global NASH (Pre- fibroctic and early- stage fibrosis) Diagnosed Cases ; 2015-2035E (In Million)
  • 5. Global NASH Off - Label Drug Market by Value ; USD Million In ( 2012-2019E)
  • 6. Global NASH Off - Label Drug Market by Region ; USD Million In ( 2012-2019E)
  • 7. Global GFT 505 Market by Value: 2017E-2030E ( USD Billion)
  • 8. GFT 505 Estimated Valuation: In USD Million
  • 9. GFT505 Market by Value: 2020E- 2030E ( USD Million)
  • 10. Aramchol Market by Value: 2021E- 2035E ( USD Million)
  • 11. Aramchol Market by Volume: 2021E- 2035E ( in Thousand)
  • 12. GR-MD-02 Market by Value; 2021E-2030E (US$ Million)
  • 13. The US NAFLD Population; 2015-2035E (In Million)
  • 14. The US NASH Population; 2015-2035E (In Million)
  • 15. Diagnose Rate of NASH in the US; 2021E-2028E (In %)
  • 16. Treatment Rate of NASH in the US; 2021E- 2028E IN Percentage
  • 17. The US NASH of -Label Drug Market By Value; 2012-2017E (USD Million)
  • 18. The US NASH Market By Value; 2019-2030E (USD Billion)
  • 19. Aramchol Sales in the US; 2021E- 2035E ( USD Million)
  • 20. Number of Patient Receiving Aramchol Treatment in the US: 2021E- 2035E In Thousands
  • 21. Aramchol Penetration Rate in US; 2021E - 2035E
  • 22. Aramchol Cost of Treatment in US; 2021E- 2035E In Thousands
  • 23. GFT 505 Net Sales in the North America : 2020E- 2030E ( USD Million)
  • 24. GR-MD-02 Sales in US: 2021E-2033E ( USD Billion )
  • 25. Number of Patient Receiving GR-MD-02 Treatment in US: 2021E-2033E In Thousand
  • 26. GR-MD-02 Annual Cost of Treatment in the US: 2021E-2035E In Thousands
  • 27. Europe NAFLD Population: 2015-2035E In Million
  • 28. Europe NASH Population: 2015-2035E ( In Million)
  • 29. Europe NASH Pre- Firoctics & Early Fibrosis Cases: 2015-2035E In Million
  • 30. Europe NASH Prevalence Rate In Percentage 2021E-2028E
  • 31. Europe NASH Diagnosed Cases: 2015-2035E In Million
  • 32. Europe Diagnosis Rate 2021E-2028E
  • 33. Europe Treatment Rate of NASH in Europe: 2021E-2028E In Percentage
  • 34. Europe NASH Market by Value: 2012-2019E USD Million
  • 35. Europe Treatment Rate of NASH in Europe: 2021E-2028E In Percentage
  • 36. Europe NASH Market By Value: 2021E-2030E USD Billion
  • 37. Europe NASH Market by Value: 2012-2019E USD Million
  • 38. Europe NASH Market By Value: 2021E-2030E USD Billion
  • 39. Europe Aramchol Penetration Rate in Europe: 2021E-2035E In Percentage
  • 40. Europe Aramchol Annual Cost Of Treatment in Europe : 2021E-2035E In Thousands
  • 41. Europe NASH Market By Value: 2021E-2030E USD Billion
  • 42. Japan NASH Therapeutics Market by Value: 2023E- 2030E USD Billion
  • 43. Galmed Pharmaceuticals Share Price 25th November 2015- 25 November 2014
Back to Top